Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Single-arm, Dose Escalation and Expansion, Phase I/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SNUG01 in Adult Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT07169175 is registered in ClinicalTrials.gov with SineuGene Therapeutics Co., Ltd. as lead sponsor.

NCT NCT07169175
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07169175 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Single-arm, Dose Escalation and Expansion, Phase I/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SNUG01 in Adult Subjects With Amyotrophic Lateral Sclerosis (ALS)
Lead sponsor
SineuGene Therapeutics Co., Ltd.
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
December 1, 2025
Completion date
September 30, 2028
Enrollment
21 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

amyotrophic lateral sclerosis (als)